Impact and cost-effectiveness of an injectable rotavirus vaccine candidate compared to oral rotavirus vaccines

Author
Language
Published
2021

Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced clinical development include injectable next-generation rotavirus vaccines (iNGRVs), which have the potential to better protect children against disease, be combined with existing routine immunizations, and be even more affordable than the current LORVs. PATH conducted a series of studies to understand the real public health value of iNGRVs to help inform decisions by international agencies, funders, vaccine manufacturers, and countries. This included an impact and cost-effectiveness analysis examining multiple rotavirus vaccine options and strategies. This fact sheet provides an overview of the results.